#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Precursor T-lymphoblastic lymphoma/leukaemia recurrent Endocrine ophthalmopathy Hyperadrenocorticism Metastatic gastric cancer B-cell type acute leukaemia Bile acid synthesis disorder Proteus syndrome Leukoencephalopathy Neuroendocrine carcinoma Li-Fraumeni syndrome C3 glomerulopathy Giant cell tumour of tendon sheath Eosinophilic granulomatosis with polyangiitis Oesophageal squamous cell carcinoma stage II Becker's muscular dystrophy More trials…

    Learn about Rare Diseases

    Haemophilia B without inhibitors – Basic Information Mucopolysaccharidosis – Diagnostics Anaplastic thyroid cancer Anaplastic thyroid cancer – Life with Disease Hypereosinophilic syndrome – Diagnostics Hepatoblastoma – Basic Information Congenital hypotransferrinaemia – Trials in Disease Hepatic angiosarcoma – Treatment Undifferentiated sarcoma – Life with Disease Cystic fibrosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    177LU-PSMA-I&T Nemolizumab Levobupivacaine Rbl007.2 Rotigotine Siplizumab Flortaucipir (18F) Ulonivirine Birtamimab Riboflavin Sodium Phosphate Elotuzumab S227928 Eclitasertib IMA401 Tapderimotide Fostemsavir VTX2735 SODIUM Eight Treg Pbf-999 Citalopram Hydrobromide More therapies…

    Learn about Your Condition

    Bladder cancer Craniocerebral injury Albuminuria Adrenocortical carcinoma B-cell type acute leukaemia Thymoma Glaucoma Peyronie's disease Compulsive sexual behaviour Malignant lymphoid neoplasm Neurodegenerative disorder Oropharyngeal cancer recurrent Transferrin decreased Non-Hodgkin's lymphoma Hereditary optic atrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hospital Jihlava

Hospital Jihlava

Vrchlickeho 59, Jihlava, 586 01, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Muscle spasticity
    Investigated Drugs:
    • Botulinum Toxin Type A – Haemagglutinin Complex
    • Clostridium Botulinum, Neurotoxin Serotype A/B
    Austria Bulgaria Czechia France Germany Hungary +4

  • Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

    Recruiting

    3 1 1
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Edoxaban for Patients with Atrial Fibrillation and Previous Brain Bleeding

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    • Haemorrhage intracranial
    Investigated Drugs:
    • Edoxaban
    Austria Belgium Czechia Denmark Germany Greece +4

  • Study Comparing CT-P53 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Cetirizine Dihydrochloride
    • Methylprednisolone
    • Ocrelizumab
    Bulgaria Croatia Czechia Poland Romania Spain

  • Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

    Not recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Bulgaria Czechia Denmark France +14

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!